There are plenty of opportunities for investors if they follow us here at Insider Financial.
The key to trading stocks is finding the momentum BEFORE it happens and then being patient. Now, when we say that we find momentum BEFORE it happens, we are investors looking to position our subscribers BEFORE the move happens.
It’s also best to own a portfolio of penny stocks. For some that can be as many as 10 to 20 or more stocks that include both OTC stocks and NASDAQ stocks.
We alert our subscribers with our best ideas before our regular readers. This is the value of having a subscription to Insider Financial, which you can sign up for here.
The fact is that there is always a bull market somewhere. That’s why it’s important for investors to trade both OTC and NASDAQ stocks, and sometimes get exposure to larger companies that still seem to have massive growth potential. There are always opportunities if you give yourself the flexibility to trade all markets.
In this article, we take a look at 4 hot NASDAQ stocks. They are Cumberland Pharmaceuticals Inc (NASDAQ: CPIX), Insignia Systems, Inc (NASDAQ: ISIG), Lightwave Logic, Inc (NASDAQ: LWLG), and Progenity, Inc (NASDAQ: PROG).
NASDAQ STOCKS #1 CPIX
Cumberland Pharmaceuticals Inc surged on Tuesday to the highest level in over two years, breaking above $7 before correcting to the current level at $5.72. Interestingly, the rebound took off at the end of November, when the stock touched the lowest level on record near $2.00 as a result of a long-term bearish trend.
CPIX, which has been around for over two decades, is a specialty pharmaceutical company that focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and rheumatology in the US and internationally.
Cumberland provides the following products:
- Acetadote – an injection for the treatment of acetaminophen poisoning;
- Caldolor – an injection for the treatment of pain and fever;
- Kristalose – a prescription laxative used for the treatment of chronic and acute constipation;
- Omeclamox-Pak – it is used for the treatment of Helicobacter pylori infection and duodenal ulcer disease;
- Vaprisol – an injection for treating euvolemic and hypervolemic hyponatremia;
- Vibativ – an injection that is used to treat certain serious bacterial infections.
It also develops RediTrex – an injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis.
The recent price spike came after the CPIX announced that the Food and Drug Administration (FDA) had approved expanded labeling for Caldolor, an intravenously delivered formulation of ibuprofen, to now include use in pre-operative administration. The non-narcotic pain reliever may now be administered just prior to surgery to enable patients to wake up from their procedure in significantly less pain.
The newly FDA-approved label includes information regarding the product’s indications and usage, appropriate patient populations, clinical study results, potential side effects, patient safety details, and instructions for use in pregnant women, children, and other populations.
Supporting this expanded use of Caldolor, a study of orthopedic surgical pain confirmed the significant pain reduction when the product was administered every six hours (started pre-operatively) with supplemental morphine available on an as-needed basis.
Investors jumped on the stock as they expect that Caldolor will be administered pre-operatively more often, which will contribute to the company’s revenue, which has been increasing slowly but steadily during the last years, even though the company remains unprofitable. The recent price surge came amid record volume figures, with over 200 million shares changing hands on November 30 alone.
The $85 million company has a healthy balance sheet and much room for growth with its diverse portfolio of products.
NASDAQ STOCKS #2 ISIG
Insignia Systems, Inc has also updated its YTD high after trading close to the lowest level in about two years. The share price of the $40 million company has more than doubled on Wednesday alone, currently trading at $24.61, the highest in over five years. On Tuesday, ISIG was trading at about $10, and it fluctuated near $5 last week.
Insignia offers in-store and digital advertising solutions to consumer-packaged goods manufacturers, retailers, shopper marketing agencies, and brokerages in the US. It provides the following:
- In-store signage solutions, which offers point-of-purchase services;
- Merchandising solutions that include various corrugate displays, side caps, free-standing shippers, and customized end-cap solutions;
- On-pack solutions, which include BoxTalk, coupons, recipes, and cross-promotions;
- Digital solutions, such as mobile programmatic advertising services.
On Monday, the share price started to surge after the company announced that it was initiating a formal process to explore strategic options to maximize shareholder value. Potential strategic alternatives that may be evaluated include an acquisition, merger, business combination, in-licensing, or other strategic transaction.
While the company hasn’t provided any timetable or additional details about any potential deal, investors feel that Insignia is onto something. The Board of Directors is about to approve a definitive course of action or it is determined that other disclosure is appropriate.
ISIG may increase the value of your portfolio in the long term as the company decides which way to go, but the best time to get exposure is during a correction.
— DekmarTrades via TradeCaster (@DekmarTrades) December 8, 2021
NASDAQ STOCKS #3 LWLG
Lightwave Logic, Inc is turning into a $2 billion company, and our readers and subscribers may be familiar with it. The last time when we covered it in September, the price was fluctuating near $10, and it is now trading at $18.38, which is the highest on record. We also paid attention to this stock in June when it was trading below $2.5 and was not even listed on NASDAQ.
LWLG is a development stage company that is nearing commercialization of a portfolio of organic, nonlinear electro-optical, and all-optical polymers (plastic), which have the ability to alter light waves for various optical applications. Initial use of this material is for the conversion of digital information into light pulses at speeds that are orders of magnitude faster than conventional materials, which are based on the nonlinear capabilities of inorganic materials. In addition to developing materials for integration into customer contemplated designs, the company is using these advanced materials as the basis for a series of proprietary, advanced integrated optical devices and sub-systems that have broad application in telecommunications, data communications and optical computing for applications in both military and commercial markets.
In a nutshell, the company uses its proprietary electro-optic (EO) polymers to transmit data at higher speeds with less power.
LWLG promotes its products to electro-optic device manufacturers, including telecommunication component and systems manufacturers, semiconductor companies, computing companies, and government agencies.
LWLG has seen its earnings declining during the last few years, but it has a strong balance sheet. The company has several patents for its materials, devices, and methodology. With about three decades of experience in its narrow field, LWLG has a long-term goal to power faster networks, reduce energy costs, and support flexible technologies. The company’s flagship products are only starting to be commercialized as a prototype, and the stock has tremendous upside potential.
Recently, LWLG provided an update for the third quarter, highlighting the following achievements and plans:
- The company’s cash and cash equivalents are approximately $15 million, enabling it to finance operations through March 2023.
- The stock began trading on the Nasdaq on September 1, 2021.
- LWLG achieved world-record performance for a polymer modulator, as demonstrated in an optical transmission experiment by ETH Zurich, using the company’s proprietary, advanced Perkinamine™ chromophores and Polariton Technologies Ltd’s newest plasmonic EO modulator, a silicon-photonics-based plasmonic racetrack modulator offering energy-efficient, low-loss, and high-speed modulation in a compact footprint.
- Received third-party review of the ultra-high performance of Lightwave Logic’s electro-optic polymers working with a slot modulator design.
- Fortified intellectual property portfolio, growing to over 72 domestic and international patents and patent applications in advance of future commercialization initiatives – further strengthening the company’s business model and freedom of manufacturing.
- Developed breakthrough improved thermal design properties for electro-optic polymers used in its Polymer Plus™ and Polymer Slot™ modulators, enabling the speed, flexibility, and stability needed for high-volume silicon foundry processes.
LWLG has already been a big winner for our subscribers, and it continues to grow at a fast pace. We still think it’s one of the best stocks to hold in your portfolio.
NASDAQ STOCKS #4 PROG
Progenity, Inc is another NASDAQ stock that we previously discussed, although it’s the only ticker from our list that is correcting rather than trading near YTD high. PROG is up 3% since last week but has declined by 23% since mid-November. Still, we regard PROG as a great stock with long-term potential.
Earlier this month, the biotech firm, which is innovating in the fields of gastrointestinal health and oral biotherapeutics, announced a new patent related to its single-molecule detection platform under development. The USPTO issued US Patent No. 11,186,863 entitled, “Methods, Systems, and Compositions for Counting Nucleic Acid Molecules.” The issued claims cover methods for capturing, amplifying, and imaging single copies of target nucleic acid molecules.
PROG’s Matthew Cooper explained:
“This patent covers critical methods for counting target molecules, obviating the need for sequencing. Our Single-Molecule Detection Platform is designed to enable tests such as noninvasive prenatal testing (NIPT) or liquid biopsy for cancer to be performed without the need for costly, complex sequencing, which would greatly reduce cost and simplify operational implementation. The platform also has potential applications beyond nucleic acids, such as proteins. As Progenity migrates away from the commercial diagnostics business, we are actively seeking partners to further develop this promising asset.”
The company has developed a strong patent portfolio supporting its single-molecule detection platform, including six distinct patent families that cover different aspects of its molecular counting platform and a separate family directed to detecting nucleosomal positioning patterns, which can be useful for determining cell-free DNA tissue-of-origin. These patents are part of Progenity’s corporate portfolio consisting of 96 patent families, including 180 issued patents and more than 220 pending applications.
PROG has not been profitable during the last year, but its diverse and extensive list of patents puts it in a unique position to secure several streams of income.
THE FINAL NOTE
Now is a great opportunity to invest in top stocks with great potential. Our job is to identify the best stocks with strong fundamentals and let our subscribers pick the ones they like to build a well-diversified portfolio.
Buying dips and selling rips as swing trades remains the best strategy in the stock market. Still, whenever a hot stock is in the middle of a bull run, we recommend our subscribers to book profits.
It’s very important to eye stocks that have room for growth and have yet to make their explosive move. There are plenty of opportunities, and we take our time to monitor hundreds of stocks to buy each week, trying to find the best alerts for our subscribers.
Remember, all you need is one or two stocks to run in order to crush the market averages.
As always, good luck to all (except the shorts)!
WHEN INSIDER FINANCIAL HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no position in any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.